Preadipocyte Factor-1 Is Associated with Marrow Adiposity and Bone Mineral Density in Women with Anorexia Nervosa

Pouneh K. Fazeli, Miriam A. Bredella, Madhusmita Misra, Erinne Meenaghan, Clifford J. Rosen, David R. Clemmons, Anne Breggia, Karen K. Miller, and Anne Klibanski

Neuroendocrine Unit (P.K.F., M.M., E.M., K.K.M., A.K.) and Department of Radiology (M.A.B.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114; Maine Medical Center Research Institute (C.J.R., A.B.), Scarborough, Maine 04074; and Division of Endocrinology (D.R.C.), Department of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599

Context: Despite having low visceral and sc fat depots, women with anorexia nervosa (AN) have elevated marrow fat mass, which is inversely associated with bone mineral density (BMD). Adipocytes and osteoblasts differentiate from a common progenitor cell, the human mesenchymal stem cell. Therefore, understanding factors that regulate this differentiation process may provide insight into bone loss in AN.

Objective: The objective of the study was to investigate the relationship between preadipocyte factor-1 (Pref-1), a member of the epidermal growth factor-like family of proteins and regulator of adipocyte and osteoblast differentiation, and fat depots and BMD in AN.

Design: This was a cross-sectional study.

Setting: The study was conducted at a clinical research center.

Patients: Patients included 20 women with AN (26.8 ± 1.5 yr) and 10 normal-weight controls (29.2 ± 1.7 yr).

Interventions: There were no interventions.

Main Outcomes Measure: Pref-1, leptin, IGF-I, IGF binding protein (IGF-BP)-2 and estradiol levels were measured. BMD of the spine and hip was measured by dual-energy x-ray absorptiometry. Marrow fat content of the L4 vertebra and femur was measured by 1H-magnetic resonance spectroscopy.

Results: Pref-1 levels were significantly higher in AN compared with controls (P = 0.01). There was a positive correlation between Pref-1 and marrow fat of the proximal femoral metaphysis (R = 0.50, P = 0.01) and an inverse association between leptin and L4 marrow fat (R = −0.45, P < 0.05). There was an inverse association between Pref-1 and BMD of both the anteroposterior spine and lateral spine (R = −0.54, P = 0.003; R = −0.44, P = 0.02, respectively).

Conclusions: Pref-1 is elevated in AN. Pref-1, IGF-I, IGF-BP2 and leptin are associated with marrow adiposity and BMD. (J Clin Endocrinol Metab 95: 407–413, 2010)
Anorexia nervosa (AN) is a primary psychiatric disorder, characterized by extreme self-imposed starvation, affecting 0.5–1% of college-aged women in the United States (1, 2). There are many significant medical complications and comorbidities associated with the disease, and bone loss is among the most common. An estimated 50% of women with AN have osteopenia, with an additional 35% having evidence of osteoporosis (3).

Low bone mass in adolescents and adults occurs in the setting of low sc and visceral fat depots (4), and loss of nutritionally dependent factors are important in the pathogenesis of bone loss. Recent advances in mesenchymal stem cell differentiation have demonstrated a possible inverse relationship between osteoblast differentiation and adipocyte differentiation (5, 6). Because osteoblasts and adipocytes originate from a common progenitor, the human mesenchymal stem cell (hMSC), understanding the factors that potentially regulate the differentiation process of hMSCs into bone and fat may be of great importance in understanding clinical states of low bone mass.

We have previously shown that although peripheral and visceral fat stores are low in AN, bone marrow adiposity is increased and inversely associated with bone mineral density (BMD) (7). The clinical significance of bone marrow adiposity has been shown in a number of studies. For example, Schellinger et al. (8) demonstrated that individuals with radiographic evidence of vertebral bone weakness, including wedging of vertebrae or vertebral body compression fractures, had higher percentages of vertebral marrow fat content compared with those without such findings.

Little is known about the hormonal determinants of marrow fat. We therefore investigated adipocyte factor-1 (Pref-1), an important factor in mesenchymal stem cell differentiation. We also investigated other hormonal mediators of low bone mass in AN including leptin, an adipokine linked to bone mass and decreased in AN, IGF-I, IGF binding protein (IGF-BP)-2 and estradiol. Pref-1 is a member of the epidermal growth factor (EGF)-like-family of proteins and is expressed in several progenitor cell types including hMSCs and adipocytes (9). Pref-1 is present on the extracellular membrane and is cleaved before it is released into the extracellular space to exert suppressive effects in an autocrine and paracrine manner on adipocyte and osteoblast differentiation (10, 11). Interestingly, Pref-1 circulates in relatively high concentrations, although it is unclear how the circulating levels relate to target tissues. IGF-I is a nutritionally dependent hormone that is known to stimulate bone formation through effects on osteoblastic function (12–14). IGF-BP2 is one of the six IGF-BPs that binds IGF-I in the circulation and has been previously shown to be abnormally elevated in adult women with AN (15–17) and has been shown to be inversely associated with markers of bone formation in AN (16). Although estrogen therapy has not been shown to increase BMD in women with AN (18, 19), estrogen therapy in postmenopausal women has been shown to decrease marrow adipocyte volume and prevent increases in marrow adipocyte number (20). Leptin has been shown to increase trabecular bone volume and trabecular number in ovariectomized rats when administered peripherally (21). In humans with hypothalamic amenorrhea, a state characterized by low leptin levels, treatment with leptin has been shown to increase markers of bone formation including osteocalcin and bone-specific alkaline phosphatase (22). Given the phenotypic nature of AN with very little peripheral adipose tissue, low leptin, and reduced bone formation, we hypothesized that Pref-1, leptin, IGF-I, IGF-BP2 and estradiol would be associated with marrow adiposity in AN.

Subjects and Methods

Subjects

Thirty women were studied: 20 women with AN (aged 19–41 yr) and 10 normal-weight controls of comparable age (aged 25–42 yr). The 20 women with AN were recruited through referrals from local eating disorder providers and on-line advertisements, and the 10 normal-weight controls were recruited through on-line advertisements. Subjects met Diagnostic and Statistical Manual of Mental Disorders, fourth edition, weight and psychiatric criteria for AN. None of the subjects had received estrogen within 3 months of the study. All control subjects had a normal body mass index (BMI), a history of regular menstrual cycles and were receiving no medications known to affect bone mass. Control subjects did not have a past or present history of an eating disorder. Subjects with abnormal TSH, elevated FSH, chronic diseases known to affect BMD (other than AN), or diabetes mellitus were excluded from participation.

All subjects were examined and blood was drawn for laboratory studies at a single study visit at our Clinical Translational Science Center. Height was measured as the average of three readings on a single stadiometer, and subjects were weighed on an electronic scale while wearing a hospital gown. BMI was calculated using the formula [weight (kilograms)/height (meters)2].

The study was approved by the Partners Institutional Review Board and complied with the Health Insurance Portability and Accountability Act guidelines. Written informed consent was obtained from all subjects. The clinical characteristics and magnetic resonance imaging and dual-energy x-ray absorptiometry (DXA) data of nine subjects with AN and all of the control subjects have been previously reported (7).

Biochemical assessment

Pref-1 was measured with the QuantiKine human Pref-1 immunoassay (ELISA) (R&D Systems, Minneapolis, MN) with a mean minimum detectable level of 0.012 ng/ml and intraassay...
coefficient of variation (CV) of 3.1–4.3%. RIA was used to measure serum leptin (Linco Diagnostics, Inc., St. Louis, MO; sensitivity 0.5 ng/ml, CV 3.4–8.3%). Estradiol was measured by automated immunoassay (ARCHITECT; Abbott Diagnostics, Chicago, IL) with a minimum reportable concentration of 10 pg/ml with interassay CV of 2–9.6%. IGF-I and IGF-BP2 were measured by RIA in the laboratory of David Clemmons (Chapel Hill, NC) as previously described (23). The intraassay CV for IGF-I was 3.3% and the interassay CV was 5.4% (23). For IGF-BP2, the intraassay CV was 5.6% and the interassay CV was 5.9% (23).

Radiological imaging
All control subjects and a subset of 10 women with AN underwent 1H-magnetic resonance spectroscopy of bone marrow of the L4 vertebral body, the proximal femoral epiphysis, metaphysis, and diaphysis to determine lipid content using a 3.0T magnetic resonance imaging system (Siemens Trio, Siemens Medical Systems, Erlangen, Germany); fitting of the 1H-magnetic resonance spectroscopy data were performed using LC-Model software (version 6.1–4A; Stephen Provencher, Oakville, Ontario, Canada) as previously described (7). A single axial magnetic resonance imaging slice through the abdomen at the level of L4 and a single slice through the midthigh were obtained (Siemens Trio, 3T; Siemens Medical Systems) to determine abdominal sc adipose tissue (SAT), visceral adipose tissue (VAT), and total adipose tissue (TAT) as well as SAT of the thigh.

All subjects (20 with AN and 10 healthy controls) underwent DXA to measure BMD of the anteroposterior (AP) lumbar spine (L1-L4), lateral spine (L2-L4), distal radius, total hip, femoral neck, and total body and body composition including fat mass (kilograms), lean mass (kilograms), and percent body fat using a DXA to measure BMD of the anteroposterior (AP) lumbar spine (L1-L4), lateral spine (L2-L4), distal radius, total hip, femoral neck, and total body and body composition including fat mass (kilograms), lean mass (kilograms), and percent body fat using a Discovery A densitometer (Hologic Inc., Waltham, MA). CVs of DXA have been reported as less than 1% for bone (24), 1.1% for fat mass (125).

Statistical analysis
Statistical analysis was performed using JMP software (SAS Institute, Cary, NC). The means and SEM measurements were calculated for AN and the control group, and the means were compared using the Student’s t test. Correlations are for the group as a whole unless otherwise noted. Where data were not normally distributed, we either performed a transformation to approximate a normal distribution or used nonparametric tests. Log transformations were performed for leptin, abdominal SAT, VAT, and TAT.

Results

Clinical characteristics
Clinical characteristics of the study subjects are presented in Table 1. Subjects with AN had lower weight, BMI, percent ideal body weight and percent body fat compared with controls.

Hormonal parameters
Pref-1, leptin, and estradiol
Pref-1 was significantly higher in AN compared with controls [AN: 0.46 ± 0.03 ng/ml (mean ± 1 SEM) vs. control: 0.13 ± 0.03 ng/ml, P = 0.03] (Fig. 1A). Leptin was significantly lower in AN compared with controls (AN: 26.8 ± 1.5 ng/ml, control: 29.2 ± 1.7 ng/ml, P = 0.13) (Fig. 1B). Estradiol levels were significantly lower in AN than healthy controls (median estradiol level in AN 5.9%, interquartile range: 34.5% vs. healthy controls 61.7%, P < 0.0001).

IGF-I and IGF-BP2
IGF-I was significantly lower in AN compared with controls (AN: 2.3 ng/ml, control: 6.4 ng/ml, P = 0.02) (Fig. 1B). Estradiol levels were significantly lower in AN than healthy controls (median estradiol level in AN 5.9%, interquartile range: 34.5% vs. healthy controls 61.7%, P < 0.0001).

Hormonal parameters associated with body composition
Percent body fat as measured by DXA, VAT and SAT were significantly lower in AN compared with the controls (Table 1). VAT as well as SAT of the thigh were also sig-
significantly lower in AN compared with controls (Table 1). There was an inverse correlation between Pref-1 and percent body fat (Fig. 2) and a positive association between leptin and percent body fat (R = 0.84, P < 0.0001), SAT of the abdomen (R = 0.63, P < 0.005), VAT of the abdomen (R = 0.52, P < 0.03), TAT of the abdomen (R = 0.63, P = 0.005), and SAT of the thigh (R = 0.76, P = 0.0002). There was a significant positive association between estradiol and percent body fat (Spearman’s rho: 0.49, P = 0.007). There was also a significant positive correlation between IGF-I and percent body fat (R = 0.51, P = 0.02). There were no correlations between IGF-I and VAT, SAT, or TAT of the abdomen or SAT of the thigh, and there were no significant correlations between IGF-BP2 and percent body fat or VAT, SAT, or TAT of the abdomen or SAT of the thigh.

Hormonal parameters associated with bone marrow fat content

There was a positive correlation between Pref-1 and marrow fat of the proximal femoral metaphysis (R = 0.50, P = 0.01) (Fig. 3A). There was a negative correlation between leptin and marrow fat of L4 (Spearman’s rho = -0.45, P < 0.05) (Fig. 3B). There was a significant inverse association between IGF-I and marrow fat of L4 in AN (R = -0.70, P = 0.02) and a positive correlation between IGF-I and L4 marrow adiposity in the controls (R = 0.76, P = 0.01). There was a significant positive association between IGF-BP2 levels and marrow adiposity of L4 (R = -0.74, P = 0.01). There were no associations between estradiol levels and bone marrow fat content.

Hormonal parameters associated with BMD

Subjects with AN had lower BMD of the total hip, AP spine, lateral spine, and total body compared with the controls (Table 1). There was an inverse correlation between Pref-1 and BMD of the AP spine (R = -0.54, P = 0.003) (Fig. 4A) and lateral spine (R = -0.44, P = 0.02) (Fig. 4B). Significant correlations were not found between Pref-1 and BMD of the hip, distal radius, or total body. Leptin was positively correlated with BMD of the AP spine (Spearman’s rho = 0.38, P = 0.04) (Fig. 4C) and hip (Spearman’s rho = 0.42, P = 0.03) (Fig. 4D). Significant correlations were not found between leptin and BMD of the lateral spine, distal radius, or total body. In AN, Pref-1 was inversely associated with BMD of the AP spine (R = -0.51, P = 0.02), and leptin was positively correlated with hip BMD (R = 0.50, P = 0.02). Estradiol levels were positively associated with BMD of the lumbar spine (Spearman’s rho: 0.39, P = 0.04). IGF-I was positively correlated with BMD of the AP spine (R = 0.46, P = 0.048) and BMD of the hip (R = 0.49, P = 0.03) in the group as a whole and with hip BMD in AN (R = 0.65, P = 0.04). IGF-BP2 was inversely associated with BMD of the lateral spine (R = -0.48, P = 0.04) and hip (R = -0.59, P = 0.008) in the group as a whole and with BMD of the hip in AN (R = -0.64, P = 0.048).

Discussion

We have shown that women with AN have elevated levels of Pref-1. In addition, our data support the role of Pref-1 as a regulator of adipocyte and osteoblast differentiation. We have also shown that IGF-I is negatively associated with L4 marrow adiposity in AN in contrast to IGF-BP2, which is positively associated with L4 marrow fat. Our data, demonstrating an inverse association between leptin and L4 marrow adiposity, support the hypothesis that the role of marrow fat is distinct from that of SC and visceral fat depots.

AN is a psychiatric disorder characterized by extreme low body weight and is associated with multiple medical comorbidities including significant bone loss. Fracture risk is also significant in this population. A prospective study of 27 women with AN demonstrated a 7-fold increased risk of nonvertebral fracture during a mean of 2 yr of follow-up (26). A retrospective population-based study demonstrated a 3-fold increased risk of fracture many years after the
agonists and glucocorticoids have been shown to induce adi-

terat low bone mass in this population is of particular

incidence of any fracture being 57% (27). Thus, under-

initial diagnosis of AN, with the long-term cumulative

We have recently shown that women with AN have

mice, and significantly reduced BMD (11). Moreover,

leptin's role as a regulator of energy stores has been

Several studies have demonstrated an inverse rela-

it is provocative that in AN, in which marrow adipose

Osteoblasts and adipocytes are derived from a common

Peroxisome proliferator-activated receptor-γ agonists and glucocorticoids have been shown to induce adi-

In turn, this process of differentiation leads to osteoblastogenesis with con-

yet it is still unclear whether this process of differ-

New evidence is also emerging that independent preosteoblast and preadipocyte

Pref-1, a member of the EGF-like family of proteins, has also been shown to be an impor-

Peroxisome proliferator-activated receptor-γ (PPAR-γ) is an important regulator of adipocyte and osteoblast differen-

Pref-1 is highly expressed in osteoblastic cell lines, preadipocytes, and hMSCs (9) and is a negative regulator of adipocyte and osteoblast differentiation. Osteoblast-specific Pref-1 overexpression in a mouse model results in significantly low-body-weight mice and significantly reduced BMD (11). Moreover, Pref-1’s role as a regulator of energy stores has been further elucidated with the finding that overexpression of Pref-1 in a mouse model leads to lower adipose tissue mass than wild-type mice but increased insulin resistance (35). Therefore, it appears that Pref-1, an in vitro inhibitor of both osteoblast and adipocyte differentiation, may also be an important in vivo regulator of several metabolic processes.

Leptin, which is a major regulator of appetite, has been shown to be decreased in AN, most likely as a result of reduced total body fat (36). With respect to the skeleton, leptin acts centrally to enhance sympathetic tone and reduce bone formation, although leptin may also have direct effects on distinct skeletal sites (21, 37, 38). Our findings of a positive association between leptin and BMD in the low leptin state of AN are consistent with findings that leptin, when provided sc to women with low leptin levels, stimulates markers of bone formation (22) and with observational studies that demonstrate a positive association between leptin levels and bone mass in postmenopausal women (39). Our finding that leptin is inversely associated with marrow fat is also consistent with in vitro studies in which leptin blocks hMSC differentiation into adipocytes and stimulates osteogenesis (40). Whereas we found an inverse association between leptin and marrow fat at an axial site, we did not find an association between leptin and a peripheral site of marrow fat. One explanation for
this may be that the sample size of our study population was simply too small to detect this difference. Another possible explanation is that leptin acts differentially at different marrow fat sites. Hamrick et al. (38) demonstrated that when compared with wild-type mice, leptin-deficient ob/ob mice had increased marrow adipocyte number in the femur, whereas in the vertebra there was decreased marrow adipocyte number. Therefore, it is possible that leptin is differentially associated with the various marrow deposits in the human as well.

IGF-I is known to be a stimulator of osteoblastogenesis (12–14) and is known to be low in states of nutritional deprivation, such as AN (15, 16), whereas IGF-BP2, a binding protein that binds to IGF-I in the circulation, has been shown to be elevated in adults with AN (15–17). We have shown that IGF-I is positively associated with BMD of the spine and hip and is inversely associated with L4 marrow adiposity in AN and that IGF-BP2 is positively associated with marrow adiposity. Interestingly, IGF-I was positively associated with L4 marrow adiposity in healthy controls, suggesting that IGF-I may have differential actions, depending on an individual’s nutritional state and/or the hormonal milieu.

There are several limitations to our study. First, this was a cross-sectional study, and therefore, we cannot determine causation based on these data; therefore, all of the relationships demonstrated in this study are purely associative and cannot imply causation. Second, the source of Pref-1 is not clear from our studies. It is possible that Pref-1, which is found in high levels in preadipocytes, is cleaved during the maturation process and released into the circulation, explaining the elevated levels of circulating Pref-1 observed in anorexia nervosa. Yet Pref-1 is synthesized in several tissues, including the liver, and therefore, we cannot exclude the possibility that this EGF-like protein from other tissue sources may contribute to the suppressed bone formation reported in AN. Third, any conclusions about leptin’s effects on bone have to be tempered by the complex nature of its relationship to hypothalamic processing and sympathetic signaling. Fourth, because only a single estradiol level was measured, definitive conclusions regarding the relationship between estradiol and marrow adiposity cannot be made. Given the exploratory nature of our study, further studies, involving larger study populations, will be needed in further understanding the association between Pref-1, leptin, and marrow fat.

In conclusion, our data demonstrate that women with AN have significantly higher levels of Pref-1, an important negative regulator of adipocyte and osteoblast differentiation. We have shown that Pref-1 is associated with marrow adiposity and low bone mass. Further understanding of the role of Pref-1 as a possible mediator of adipocyte and osteoblast differentiation may be of significant clinical importance.

Acknowledgments

We thank the nurses and bionutritionists of the Massachusetts General Hospital Clinical Research Center for their expert care. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health.

Address all correspondence and requests for reprints to: Anne Klibanski, M.D., Neuroendocrine Unit, Bulfinch 457B, Massachusetts General Hospital, Boston, Massachusetts 02114. E-mail: aklibansk@partners.org.

This work was supported by Grant U1U RR025758 from the National Center for Research Resources (to Harvard Clinical and Translational Science Center), and Grants R01 DK052625, R01 HL077674, M01 RR01066, UL1 RR0257801, and T32 DK007028 from the National Institutes of Health.

Disclosure Summary: The authors have no conflicts to declare.

References

1. Lucas AR, Beard CM, O’Fallon WM, Kurland LT 1991 50-year trends in the incidence of anorexia nervosa in Rochester, Minn.: a population-based study. Am J Psychiatry 148:917–922
2. Pope HG JH, Yurgelun-Todd D, Hudson MS 1984 Prevalence of anorexia nervosa and bulimia in three student populations. Int J Eating Disord 3:45–51
3. Miller KK, Grinspoon SK, Ciampa J, Hier J, Herzog D, Klibanski A 2005 Medical findings in outpatients with anorexia nervosa. Arch Intern Med 165:561–566
4. Mayer L, Walsh BT, Pierson Jr RN, Heysmfield SB, Gallagher D, Wang J, Parides MK, Leibel RL, Warren MP, Killory E, Glaser A 2005 Body fat redistribution after weight gain in women with anorexia nervosa. Am J Clin Nutr 81:1286–1291
5. Beresford JN, Bennett JH, Devlin C, Leboy PS, Owen ME 1992 Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures. J Cell Sci 102(2Pt):341–345
6. Verma S, Rajaratnam AMH, Denton J, Hoyland JA, Byers RJ 2002 Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis. J Clin Pathol 55:693–698
7. Bredella MA, Fazeli PK, Miller KK, Misra M, Torriani M, Thomas BJ, Hosseini Ghomi R, Rosen CJ, Klibanski A 2009 Increased bone marrow fat in anorexia nervosa. J Clin Endocrinol Metab 94:2129–2136
8. Schellinger D, Lin CS, Hatipoglu HG, Fertik D 2001 Potential value of vertebral proton MR spectroscopy in determining bone weakness. AJNR Am J Neuroradiol 22:1620–1627
9. Abdallah BM, Jensen CH, Gutierrez G, Leslie RG, Jensen TG, Kassem M 2004 Regulation of human skeletal stem cells differentiation by Dlk1/Pref-1. J Bone Miner Res 19:841–852
10. Wang Y, Kim KA, Kim JH, Sul HS 2006 Pref-1, a preadipocyte secreted factor that inhibits adipogenesis. J Nutr 136:2953–2956
11. Abdallah BM, Ditzel N, Traustadottir GA, Schilling AF, Amling M, Kassem M Dlk1/PF1A is a novel factor enhancing osteoclastogenesis and inhibiting bone formation in vitro and in vivo. Proc 30th Annual
Meeting of the American Society for Bone and Mineral Research, 2008, Abstract 1007:S3
12. Bennett A, Chen T, Feldman D, Hintz RL, Rosenfeld RG 1984 Characterization of insulin-like growth factor I receptors on cultured rat bone cells: regulation of receptor concentration by glucocorticoids. Endocrinology 115:1577–1583
13. Canalis E 1980 Effect of insulin-like growth factor I on DNA and protein synthesis in cultured rat calvaria. J Clin Invest 66:709–719
14. Hock JM, Centrella M, Canalis E 1988 Insulin-like growth factor I has independent effects on bone matrix formation and cell replication. Endocrinology 122:254–260
15. Counts DR, Gwirtsman H, Carlsson LM, Lesem M, Cutler Jr GB 1992 The effect of anorexia nervosa and refeeding on growth hormone-binding protein, the insulin-like growth factors (IGFs), and the IGF-binding proteins. J Clin Endocrinol Metab 75:762–767
16. Hotta M, Fukuda I, Sato K, Hizuka N, Shibasaki T, Takano K 2000 The relationship between bone turnover and body weight, serum insulin-like growth factor (IGF) I, and serum IGF-binding protein levels in patients with anorexia nervosa. J Clin Endocrinol Metab 85:200–206
17. Grinspoon S, Miller K, Herzog D, Cleemmons D, Klibanski A 2003 Effects of recombinant human insulin-like growth factor (IGF)-I and estrogen administration on IGF-I, IGF binding protein (IGFBP)-2, and IGFBP-3 in anorexia nervosa: a randomized-controlled study. J Clin Endocrinol Metab 88:1142–1149
18. Klibanski A, Biller BM, Schoenfeld DA, Herzog DB, Saxe VC 1995 The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J Clin Endocrinol Metab 80:898–904
19. Grinspoon S, Thomas L, Miller K, Herzog D, Klibanski A 2002 Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J Clin Endocrinol Metab 87:2883–2891
20. Syed FA, Oursler MJ, Hefferan ME, Peterson JM, Riggs BL, Khosla S 2008 Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women. Osteoporos Int 19:1323–1330
21. Burguera B, Hofbauer LC, Thomas T, Gori F, Evans GL, Khosla S, Riggs BL, Turner RT 2001 Leptin reduces ovarioectomy-induced bone loss in rats. Endocrinology 142:3546–3553
22. Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, Karalis A, Mantzoros CS 2004 Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med 351:987–997
23. Smith WJ, Underwood LE, Cleemmons DR 1995 Effects of caloric or protein restriction on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in children and adults. J Clin Endocrinol Metab 80:443–449
24. Barthe N, Braillon P, Ducassou D, Basse-Cathalanit B 1997 Comparison of two Hologic DXA systems (QDR 1000 and QDR 4500/ A). Br J Radiol 70:728–739
25. Johnson J, Dawson-Hughes B 1991 Precision and stability of dual-energy X-ray absorptiometry measurements. Calcif Tissue Int 49:174–178
26. Rigotti NA, Neer RM, Skates SJ, Herzog DB, Nussbaum SR 1991 The clinical course of osteoporosis in anorexia nervosa. A longitudinal study of cortical bone mass. JAMA 265:1133–1138
27. Lucas AR, Melton 3rd LJ, Crowson CS, O’Fallon WM 1999 Long-term fracture risk among women with anorexia nervosa: a population-based cohort study. Mayo Clin Proc 74:972–977
28. Di Iorgi N, Mittelman SD, Gilsanz V 2008 Differential effect of marrow adiposity and visceral and subcutaneous fat on cardiovascular risk in young, healthy adults. Int J Obes (Lond) 32:1834–1860
29. Shen W, Chen J, Punyanitya M, Shaptes S, Heshka S, Heymsfield SB 2007 MRI-measured bone marrow adipose tissue is inversely related to DXA-measured bone mineral in Caucasian women. Osteoporos Int 18:641–647
30. Di Iorgi N, Rosol M, Mittelman SD, Gilsanz V 2008 Reciprocal relationship between marrow adiposity and the amount of bone in the axial and appendicular skeleton of young adults. J Clin Endocrinol Metab 93:2281–2286
31. Rzona SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B 2004 Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145:401–406
32. Mazziotti G, Angeli A, Bilezikian JP, Canalis E, Giustina A 2006 Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 17:144–149
33. Dang ZC, van Beuzoijen RL, Karperien M, Papapoulos SE, L¨owik CW 2002 Exposure of K5483 cells to estrogen enhances osteogenesis and inhibits adipogenesis. J Bone Miner Res 17:394–405
34. Post S, Abdallah BM, Bentonz JE, Kassem M 2008 Demonstration of the presence of independent pre-osteoblastic and pre-adipocytic cell populations in bone marrow-derived mesenchymal stem cells. Bone 43:32–39
35. Villena JA, Choi CS, Wang Y, Kim S, Hwang YJ, Kim YB, Cline G, Shulman GI, Sul HS 2008 Resistance to high-fat diet-induced obesity but exacerbated insulin resistance in mice overexpressing preadipocyte factor-1 (Pref-1): a new model of partial lipodystrophy. Diabetes 57:3258–3266
36. Grinspoon S, Gulick T, Askari H, Landt M, Lee K, Anderson E, Ma Z, Vignati L, Bowsher R, Herzog D, Klibanski A 1996 Serum leptin levels in women with anorexia nervosa. J Clin Endocrinol Metab 81:3861–3863
37. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G 2000 Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100:197–207
38. Hamrick MW, Pennington C, Newton D, Xie D, Isales C 2004 Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone 34:376–383
39. Blain H, Vuillemin A, Guillemain F, Durant R, Hanesse B, de Talance N, Doucet B, Jeandel C 2000 Serum leptin level is a predictor of bone mass in women with primary amenorrhea. Osteoporos Int 10:1248–1254
40. Thomas T, Gori F, Khosla S, Jensen MD, Burguera B, Riggs BL 1999 Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology 140:1630–1638

Downloaded from https://academic.oup.com/jcem/article-abstract/95/1/407/2835399 by guest on 15 March 2020